Protective effect of @entity1421 in the gastrointestinal tract during XXXX treatment of @entity627 .

@entity1 @entity627 @entity548 @entity190 @entity1421 @entity344 @entity2918 @entity460 @entity3352 @entity360 @entity356
Nonsteroidal antiinflammatory drugs (NSAID) induce the formation of @entity548 @entity356 and intestinal ulcers in experimental animals. The damage can be prevented by prior local administration of @entity2918 , indicating that @entity2918 have protective properties on the @entity344 . The protective effect was studied in @entity1 by measuring the fecal @entity190 during @entity3352 treatment of 18 @entity1 with @entity627 with and without concomitant oral supplementation with 1 mg @entity1421 three times daily. The study had a randomized double-blind crossover design using 51Cr-labeled erythrocytes as marker of @entity360 . @entity3352 increased the daily fecal @entity190 from 1.0 +/- 0.3 to 2.8 +/- 0.6 ml (P less than 0.005). When oral @entity1421 was taken concomitantly, the @entity190 was reduced to 1.1 +/- 0.2 ml daily (P less than 0.01), i.e., to the control level. Side effects of @entity1421 were negligible, and the beneficial effect of @entity3352 on joint status and symptoms was not interfered with. No changes were recorded in repeated blood tests except for a slightly reduced hemoglobin and a small but statistically significant reduction of serum- @entity460 during @entity3352 treatment, an effect hitherto not described in normocalcemic @entity1 subjects. A protective effect on the @entity344 by oral @entity1421 has by the present study been demonstrated also in @entity1 . The protection is unrelated to the @entity356 acid secretion, which is not inhibited by oral @entity1421 . The finding may have clinical application, as gastrointestinal side effects and @entity548 are common reasons for discontinuation of NSAID in @entity1 with @entity627 .
